Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trial
We have previously reported on the results of the United Kingdom National Cancer Research Institute (NCRI) AML17 trial, which, for acute promyelocytic leukemia (APL) of all risk groups, compared anthracycline + all-trans retinoic acid (ATRA) (AIDA) vs arsenic trioxide (ATO) + ATRA using an attenuate...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
American Society for Haematology
2018
|